thebench.bio #1 Ecosystem for the Bio-Tech Industry

Industry Daily Summary

Industry Daily Summary: What Happened on November 5, 2026

Boehringer’s six-program cancer deal includes $358 million upfront

Evommune licensed Hinova’s oral autoimmune candidate EVO570, while Boehringer expanded its cardiovascular collaboration with Variant Bio.

  • Updated
  • Read from 6 articles, 4 publications
  • B M

Today in brief

Boehringer Ingelheim struck a deal with Sino Biopharmaceutical for six preclinical cancer programs, with up to $7 billion in potential milestone payments.12 Sino will receive $358 million upfront and in near-term payments, and Boehringer may seek rights after clinical milestones.12

Evommune obtained exclusive rights outside Greater China to Hinova’s autoimmune candidate EVO570 in a deal valued at up to about $1.1 billion.3 The oral drug is slated for Phase I testing, and Evommune plans a Phase II rheumatoid arthritis trial in 2027.3

Boehringer’s six-program deal could reach $7 billion

Boehringer Ingelheim agreed with Sino Biopharmaceutical to license six preclinical oncology programs based on antibody-drug conjugates and T-cell engagers, which direct cancer-killing activity toward tumors.12 Sino will receive $358 million upfront and in near-term payments, with up to $7 billion more tied to clinical, regulatory, and commercial milestones.12

Sino may also receive tiered royalties on sales, described as reaching double digits.14 LaNova Medicines supplied five programs, and Beijing Tide Pharmaceutical supplied one.25

Sino will lead early development, while Boehringer may take exclusive development, manufacturing, and commercialization rights after specified clinical milestones.25 Potential rights for four programs exclude mainland China, Hong Kong, and Macau. Rights for the other two may be worldwide.12

Boehringer opened a research and development center in Shanghai on October 12 to expand local early clinical development and connect Chinese research with its global drug development work.1

Evommune licenses Hinova’s oral autoimmune candidate

Evommune licensed exclusive rights outside Greater China to develop, manufacture, and commercialize Hinova’s EVO570, an oral molecular glue degrader designed to disrupt VAV1 signaling.3 The deal is valued at up to about $1.1 billion and includes $30 million upfront, split between $20 million in cash and $10 million in pre-funded warrants.3

Hinova may receive development, regulatory, and commercial milestone payments, plus royalties on sales outside Greater China.3 EVO570, formerly called HC118, has not been approved. A Phase I study is scheduled to assess safety, pharmacokinetics, and target engagement.3

Evommune chief scientific officer Jeegar Patel said the company plans to report Phase I findings and begin a Phase II rheumatoid arthritis trial in 2027.3

Also worth knowing

  • M

    Boehringer Ingelheim expanded its collaboration with Variant Bio to cardiovascular disease, raising the agreement’s potential value from an initial $120 million to more than $250 million.6

Also published